PPI Use in FSGS with Impaired Renal Function
Proton pump inhibitors should be prescribed only when there is a clear, documented indication in patients with FSGS and impaired renal function, and all patients currently on PPIs without definitive indication should undergo trial de-prescribing. 1
Indication-Based Prescribing Framework
The fundamental principle is that every patient on a PPI must have a documented, ongoing indication reviewed regularly 1. In FSGS patients with impaired renal function, this becomes even more critical given the established associations between PPI use and:
- Acute interstitial nephritis (AIN)
- Hypomagnesemia
- Potential progression to end-stage kidney disease 2
When to Prescribe PPIs in FSGS
Prescribe PPIs only for:
- Active peptic ulcer disease
- Erosive esophagitis
- Barrett's esophagus
- Pathologic hypersecretory conditions
- High-dose NSAID use with documented GI risk factors
- Dual antiplatelet therapy
Do NOT prescribe for:
- "Gastroprotection" in patients on corticosteroids alone (a common pitfall in FSGS management)
- Vague dyspepsia without documented pathology
- Prophylaxis without clear risk stratification
De-prescribing Algorithm for Current PPI Users
All FSGS patients without definitive chronic indication should undergo trial de-prescribing 1. This is particularly important because:
Discontinuation does not worsen renal function: A study of CKD patients showed no significant difference in eGFR change between PPI continuation (+3.25 mL/min/1.73 m²) and discontinuation (+1.09 mL/min/1.73 m²) groups over approximately 9 months 3
The theoretical renal benefits of stopping PPIs are not proven, but the lack of harm from discontinuation is established 3
Risk Stratification Approach
For patients requiring chronic PPI therapy:
- Use the lowest effective dose
- Attempt step-down from twice-daily to once-daily dosing 1
- Monitor for hypomagnesemia (check magnesium levels every 6-12 months)
- Document the specific indication at each visit
- Reassess need every 6-12 months
Common Pitfalls to Avoid
The biggest mistake: Continuing PPIs indefinitely after initiating high-dose corticosteroids for FSGS treatment 4. While corticosteroids are the cornerstone of primary FSGS treatment, they do not require routine PPI prophylaxis unless additional GI risk factors exist.
Second pitfall: Assuming PPIs are "protecting the kidneys" - there is no evidence for renoprotective effects, and emerging data suggests potential harm through mechanisms including gut microbiota alterations, uremic toxin accumulation, and oxidative stress 5.
Monitoring Requirements
If PPI continuation is deemed necessary:
- Document specific indication in chart
- Check serum magnesium every 6-12 months
- Monitor eGFR trends (though discontinuation studies show no significant impact) 3
- Reassess indication every 6 months minimum
- Consider H2-receptor antagonist alternatives for less severe indications
The primary care provider should own this responsibility 1, though in FSGS patients, the nephrologist often serves as the de facto primary provider and must ensure this review occurs.